Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:06 PM ET 8-K
Nasdaq/NYSE Compliance Notice Nextnrg, Inc. NXXT

Nextnrg Nasdaq/NYSE Compliance Notice

NextNRG, Inc. received a final determination from the Nasdaq Hearings Panel to delist its common stock after failing to meet the $1.00 minimum bid price and $35 million market value requirements. Trading on Nasdaq was suspended effective November 12, 2026, and the company's shares began quoting on the OTC Markets under the symbol 'NXXT'.

Counterparty
The Nasdaq Stock Market LLC
4:06 PM ET 10-Q
Financial Results AB Private Lending Fund

AB Private Lending Fund Q3 2026 Results: Net Income $5.02M, Up 40.2% YoY

AB Private Lending Fund reported a net increase in net assets resulting from operations of $8.86 million for the nine months ended September 30, 2026, compared to $9.22 million in the prior year period. Total investment income grew to $25.86 million, though net investment income per share decreased from $1.86 to $1.69 due to a higher weighted average share count.

Key figure
Net income $5.02M · +40.2% YoY
4:06 PM ET 10-Q
Financial Results First National Corp FXNC

First National Q3 2026 Results: Net Income $6.9M, Up 24.3% YoY

First National Corp reported net income of $1.25 per share for both the third quarter and the first nine months of 2026. The company maintained stable dividend payouts and saw a slight increase in total assets compared to the prior year-end, supported by growth in interest and fees on loans.

Key figure
Net income $6.9M · +24.3% YoY
4:06 PM ET 8-K
Financial Results Enveric Biosciences, Inc. ENVB

Enveric Biosciences Financial Results

Enveric Biosciences reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate EB-003. The company is completing final IND-enabling activities for EB-003, a non-hallucinogenic neuroplastogenic candidate, with plans for an IND submission and Phase 1 clinical trial.

Term
Q3 2026

“Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned IND submission and first-in-human Phase 1 clinical trial of our lead non-hallucinogenic, neuroplastogenic candidate.”

Joseph Tucker, Ph.D., Chief Executive Officer of Enveric

“The growing body of preclinical evidence reinforces our confidence in this opportunity as we complete the final IND-enabling activities and prepare to advance EB-003 toward first-in-human clinical development.”

Joseph Tucker, Ph.D., Chief Executive Officer of Enveric
4:06 PM ET 8-K
Financial Results Aptera Motors Corp SEV

Aptera Motors Financial Results

Aptera Motors reported a GAAP net loss of $14.0 million for the third quarter of 2026, with research and development spending more than doubling year-over-year. The company ended the quarter with $9.2 million in cash and highlighted a new strategic partnership with Shanghai Launch Automotive Technology to support manufacturing and contract engineering.

Term
Q3 2026

“In the third quarter we started the process of procuring parts for our first production vehicles. We also entered into a strategic partnership with Launch to support manufacturing and contract engineering, which we believe has helped lower our estimated capital needs to reach start of production and, most importantly, the capital we estimate is required to reach a production rate at which we believe we could fund ongoing operations from vehicle sales.”

Chris Anthony, Co-CEO of Aptera
4:06 PM ET 10-Q
Financial Results SenesTech, Inc. SNES

SenesTech Q3 2026 Results: Net Loss of $1.96M, Loss Widens

SenesTech, Inc. reported a net loss of $5.85 million for the nine months ended September 30, 2026, compared to $4.58 million in the prior year period, despite a 31% increase in total revenues to $2.36 million. The company's cash position decreased to $3.95 million, and management indicated that current resources are only sufficient to fund operations for approximately nine months from the filing date.

Key figure
Net loss $1.96M
4:06 PM ET 10-Q
Financial Results WisdomTree Bitcoin Fund BTCW

WisdomTree Bitcoin Fund Q3 2026 Results: Net Income $53.8M, Up 402.2% YoY

For the nine months ended September 30, 2026, the WisdomTree Bitcoin Fund reported a net decrease in net assets resulting from operations of $1,601,685, primarily driven by a net change in unrealized depreciation on bitcoin. Despite the operational loss, net assets grew to $171.9 million from $139.7 million at the start of the year, bolstered by $33.9 million in net capital share transactions.

Key figure
Net income $53.8M · +402.2% YoY
4:06 PM ET 10-Q
Financial Results Amesite Inc. AMST

Amesite Q1 2026 Results: Net Loss of $774K, Loss Widens

Amesite Inc. reported a net loss of $774,395 for the quarter ended September 30, 2026, compared to a loss of $642,266 in the prior year period, driven by increased technology and content development costs. The company's management expressed substantial doubt about its ability to continue as a going concern, noting that current cash reserves may not sustain operations for the next twelve months.

Key figure
Net loss $774K
4:06 PM ET 8-K
Other 8-K Filing Athena Technology Acquisition Corp. II ATEK

Athena Technology Acquisition Corp. II Other 8-K Filing

Athena Technology Acquisition Corp. II deposited $271.48 into its trust account to extend the deadline for completing its initial business combination by one month. This Monthly Extension moves the deadline from November 14, 2026, to December 14, 2026, and represents the sixth of nine permitted monthly extensions.

Term
1 month
4:06 PM ET 8-K
Bankruptcy & Restructuring ESS Tech, Inc. GWHT

ESS Tech Bankruptcy & Restructuring

ESS Tech, Inc. has ceased all operations and filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware. A court-appointed trustee will assume control of the company's assets for liquidation, and all employees and officers, including the CEO and CFO, have been terminated. The company stated it is unlikely that common stockholders will receive any distribution and that it will no longer file periodic reports with the SEC.

4:06 PM ET 8-K
Leadership Change Phunware, Inc. PHUN

Phunware Leadership Change

Jeremy Krol separated from Phunware, Inc. as its Chief Operating Officer, effective November 6, 2026. The departure was characterized as a separation without cause, and the company expects to negotiate a separation agreement with Mr. Krol.

4:06 PM ET 10-Q
Financial Results Morgan Stanley Bitcoin Trust MSBT

Morgan Stanley Bitcoin Trust Q3 2026 Results: Net Income $164M

The Morgan Stanley Bitcoin Trust commenced operations on April 7, 2026, and reported net assets of $873.4 million as of September 30, 2026. For the period from inception through September 30, 2026, the Trust saw a net increase in net assets from operations of $96.6 million, primarily driven by $97.5 million in unrealized appreciation on its bitcoin holdings.

Key figure
Net income $164M
4:06 PM ET 8-K
Stock Buyback Boston Beer Co Inc SAM

Boston Beer Co Announces $37.5M Stock Buyback

The Boston Beer Company entered into a Rule 10b5-1 trading plan to repurchase up to $37.5 million of its Class A Common Stock. The buyback program is scheduled to run from December 28, 2026, through March 26, 2027.

Value
$37.5M
Term
Dec 2026 - Mar 2027
4:06 PM ET 10-Q
Financial Results High Roller Technologies, Inc. ROLR

High Roller Technologies Q3 2026 Results: Net Loss of $2.78M

High Roller Technologies reported a net loss of $7.1 million for the nine months ended September 30, 2026, compared to a net loss of $0.2 million in the prior year period. Revenues decreased significantly from $15.8 million to $8.6 million year-over-year, while the company successfully completed an offering that increased cash and cash equivalents to $13.4 million.

Key figure
Net loss $2.78M
4:06 PM ET Form 4
Insider Selling Castle Biosciences Inc CSTL

Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $112K of Stock

Tobin W. Juvenal, Chief Commercial Officer, sold 3,195 shares of Castle Biosciences Inc at $35.07 a share, worth $112K in total on Nov 11, 2026. Shares held after the trade: 32,737 (-8.9%).

Value
$112K
Shares
3,195
Price
$35.07
Role
Chief Commercial Officer
Holding change
-8.9%
Trade date
Nov 11, 2026
4:05 PM ET Form 4
Insider Selling Aflac Inc AFL

Aflac Insider Japan Post Holdings Co. Ltd. Sells $1.65M of Stock

Japan Post Holdings Co. Ltd. sold 13,000 shares of Aflac Inc at $126.01 to $126.97 a share (average $126.63) in 2 transactions, worth $1.65M in total on Nov 11, 2026. Shares held after the trade: 50,108,329 (-0.0%).

Value
$1.65M
Shares
13,000
Average price
$126.63
Holding change
-0.0%
Trade date
Nov 11, 2026
4:05 PM ET Form 4
Insider Buying Vistance Networks, Inc. VISN

Vistance Networks Director Timothy T. Yates Buys $98.7K of Stock

Timothy T. Yates, Director, bought 25,000 shares of Vistance Networks, Inc. at $3.95 a share, worth $98.7K in total on Nov 12, 2026. Shares held after the trade: 248,751 (+11.2%).

Value
$98.7K
Shares
25,000
Price
$3.95
Role
Director
Holding change
+11.2%
Trade date
Nov 12, 2026
4:05 PM ET 10-Q
Financial Results Carlyle Credit Solutions

Carlyle Credit Solutions Q3 2026 Results: Net Income $39.5M, Up 22.5% YoY

Carlyle Credit Solutions reported total investment income of $66.7 million for the quarter ended September 30, 2026, and net investment income of $38.3 million. Total net assets decreased slightly to $1.74 billion from $1.77 billion at year-end 2025, primarily driven by $51.7 million in net unrealized depreciation on investments and $129.7 million in distributions to stockholders.

Key figure
Net income $39.5M · +22.5% YoY
4:05 PM ET 8-K
Investor Presentation Worthington Enterprises, Inc. WOR

Worthington Enterprises Investor Presentation

Worthington Enterprises hosted an Investor and Analyst Day on November 10, 2026, to discuss its standalone strategy and performance since its separation from the steel processing business. The company introduced updated long-term financial targets and detailed growth opportunities across its Building Performance Solutions and Trade & Specialty Solutions segments.

4:05 PM ET 10-Q
Financial Results AmperCap Acquisition Co APMC

AmperCap Acquisition Q3 2026 Results: Net Income $1.17M

AmperCap Acquisition Co's 10-Q filing for the period ending September 30, 2026, reflects its status as a blank check company with no current operations. The report details administrative expenses and interest income generated from the trust account as the company continues to evaluate potential business combination targets. No definitive merger agreements or significant changes in financial guidance were disclosed.

Key figure
Net income $1.17M
4:05 PM ET 8-K
Financial Results TRex Bio, Inc. TRXB

TRex Bio Financial Results

TRex Bio reported financial results for the third quarter of 2026, highlighting a net loss of $14.1 million and a cash position of $154.2 million. The company recently completed a $133.5 million IPO in October 2026, which extends its expected cash runway into the second half of 2029 to support its clinical pipeline, including TRB-061 and TRB-071.

Term
Q3 2026

“The positive Phase 1a results for TRB-061 demonstrated selective activation and expansion of immunoregulatory Tregs in humans, providing clinical evidence that we believe supports this approach. We are now focused on understanding whether these effects can translate into meaningful and durable disease control for patients with atopic dermatitis.”

Johnston Erwin, Chief Executive Officer of TRexBio

“With the completion of our IPO, we have the resources to advance TRB-061 toward its planned mid-2027 clinical readout and expect to bring TRB-071, which targets a distinct Treg pathway, into the clinic in the first half of 2027.”

Johnston Erwin, Chief Executive Officer of TRexBio
4:05 PM ET 10-Q
Financial Results IRulya Therapeutics Inc. IRLA

IRulya Therapeutics Q3 2026 Results: Net Loss of $27.7M, Loss Widens

IRulya Therapeutics Inc. significantly strengthened its liquidity position in the first nine months of 2026, with cash and short-term investments increasing to $105.2 million from $17.8 million at year-end 2025. The company underwent a major restructuring of its balance sheet, eliminating over $100 million in total liabilities and issuing Series C Preferred Stock valued at $143.8 million following the acquisition of Orphai Therapeutics.

Key figure
Net loss $27.7M
4:05 PM ET 10-Q
Financial Results Propanc Biopharma, Inc. PPCB

Propanc Biopharma Q1 2026 Results: Net Loss of $8.59M, Loss Widens

Propanc Biopharma reported a net loss of $8.6 million for the quarter ended September 30, 2026, compared to a $4.8 million loss in the prior year, driven largely by a significant increase in compensation and professional expenses. The company's cash position decreased to $258,366 from $832,006 at the start of the fiscal year, though it raised $2 million through the exercise of Series C warrants.

Key figure
Net loss $8.59M
4:05 PM ET 10-Q
Financial Results Air Industries Group AIRI

Air Industries Group Q3 2026 Results: Turns Profitable, Net Income $946K

Air Industries Group reported a significant turnaround in the third quarter of 2026, with net sales increasing to $14.6 million and net income reaching $946,000 compared to a loss in the prior year period. However, for the nine months ended September 30, 2026, the company still recorded a net loss of $920,000 despite a 8.7% increase in year-to-date net sales.

Key figure
Net income $946K
4:04 PM ET 8-K
Shareholder Meeting Axos Financial, Inc. AX

Axos Financial Shareholder Meeting

Axos Financial held its 2026 Annual Meeting of Stockholders on November 12, 2026, with 87.81% of eligible shares represented. Stockholders elected three Class I directors (Tamara N. Bohlig, Nicholas A. Mosich, and Edward J. Ratinoff), approved executive compensation in an advisory vote, and ratified BDO USA, P.C. as the independent auditor for fiscal year 2027.

4:04 PM ET 8-K
Leadership Change Adicet Bio, Inc. ACET

Adicet Bio Leadership Change

Dr. Andrew Sinclair resigned from the Board of Directors and its committees effective November 13, 2026, with the board size subsequently reduced from seven to six members. Following the resignation, current director Michael Grissinger was appointed to the Audit Committee and named chairperson of the Nominating and Corporate Governance Committee. The company stated the resignation was not due to any disagreements regarding operations, policies, or practices.

4:04 PM ET 8-K
Business Update Invesco Real Estate Income Trust Inc.

Invesco Real Estate Income Trust Business Update

Invesco Real Estate Income Trust Inc. (INREIT) provided its monthly update for October 31, 2026, reporting a total Net Asset Value (NAV) of approximately $670.2 million. The company disclosed NAV per share across multiple share classes, ranging from $26.06 for Class T to $28.48 for Class E, which will serve as the transaction price for December 1, 2026. The filing details the trust's portfolio composition, including $1.15 billion in real estate investments offset by $480 million in mortgage notes and credit facilities.

4:03 PM ET Form 4
Insider Selling Frontdoor, Inc. FTDR

Frontdoor CEO William C. Cobb Sells $20.4M of Stock

William C. Cobb, CEO, sold 208,747 shares of Frontdoor, Inc. at $96.69 to $99.17 a share (average $97.67) in 3 transactions, worth $20.4M in total between Nov 10, 2026 and Nov 12, 2026. Shares held after the trade: 184,335 (-34.3%).

Value
$20.4M
Shares
208,747
Average price
$97.67
Role
CEO
Holding change
-34.3%
Trade date
Nov 10, 2026 to Nov 12, 2026
4:03 PM ET 8-K
Shareholder Meeting Elicio Therapeutics, Inc. ELTX

Elicio Therapeutics Shareholder Meeting

Elicio Therapeutics held its 2026 Annual Meeting of Stockholders on November 12, 2026. Shareholders elected three Class III directors (Julian Adams, Jay R. Venkatesan, and Carol Ashe) to three-year terms and ratified Baker Tilly US, LLP as the company's independent auditor for the fiscal year ending December 31, 2026.

4:03 PM ET 10-Q
Financial Results Siebert Financial Corp SIEB

Siebert Financial Q3 2026 Results: Net Loss of $711K

Siebert Financial Corp. reported a net loss of $3.0 million for the nine months ended September 30, 2026, compared to a net income of $5.6 million in the prior year period. While total revenue grew to $79.3 million, expenses surged to $83.7 million, driven by higher employee compensation, technology costs, and one-time settlement and impairment charges.

Key figure
Net loss $711K

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.